

1

2

3

4

E

3

7

3

1

•

1

1

I

5. This Consent Agreement does not constitute a dismissal or resolution of other matters currently pending before the Board, if any, and does not constitute any waiver.

1 express or implied, of the Board's statutory authority or jurisdiction regarding any other
2 pending or future investigation, action or proceeding. The acceptance of this Consent
3 Agreement does not preclude any other agency, subdivision or officer of this State from
4 instituting other civil or criminal proceedings with respect to the conduct that is the subject
5 of this Consent Agreement.

6 6. All admissions made by Respondent are solely for final disposition of this
7 matter and any subsequent related administrative proceedings or civil litigation involving
8 the Board and Respondent. Therefore, said admissions by Respondent are not intended
9 or made for any other use, such as in the context of another state or federal government
10 regulatory agency proceeding, civil or criminal court proceeding, in the State of Arizona or
11 any other state or federal court.

12 7. Upon signing this agreement, and returning this document (or a copy thereof) to
13 the Board's Executive Director, Respondent may not revoke the acceptance of the
14 Consent Agreement. Respondent may not make any modifications to the document. Any
15 modifications to this original document are ineffective and void unless mutually approved
16 by the parties.

17 8. If the Board does not adopt this Consent Agreement, Respondent will not
18 assert as a defense that the Board's consideration of this Consent Agreement constitutes
19 bias, prejudice, prejudgment or other similar defense.

20 9. This Consent Agreement, once approved and signed, is a public record that will
21 be publicly disseminated as a formal action of the Board and will be reported to the
22 National Practitioner Data Bank and to the Arizona Medical Board's website.

23 10. Respondent acknowledges that the long-term effects of Human Growth
24 Hormone (HGH) used for the treatment of Adult HGH deficiency have not been
25

1 conclusively determined. Respondent further acknowledges that the FDA has approved
2 the use of HGH only for the treatment of a disease or other recognized medical condition.

3 11. Respondent agrees to perform regular physical exams and lab studies after
4 patients' initial visits prior to continuing medications and to more carefully address
5 abnormal clinical and laboratory findings.


6 12. If any part of the Consent Agreement is later declared void or otherwise
7 unenforceable, the remainder of the Consent Agreement in its entirety shall remain in force
8 and effect.

9 13. Any violation of this Consent Agreement constitutes unprofessional conduct
10 and may result in disciplinary action. A.R.S. § § 32-1401(27)(r) ("violating a formal order,
11 probation, consent agreement or stipulation issued or entered into by the board or its
12 executive director under this chapter") and § 32-1451.

13
14
15
16 
ELI J. HAMMER, M.D.

DATED: 3/26/09

17
18
19 Approved As To Form:

20
21 
22 Debra A. Hill
23 Attorney for Respondent
24
25

DATED: 3/26/09

1 **FINDINGS OF FACT**

2 1. The Board is the duly constituted authority for the regulation and control of
3 the practice of allopathic medicine in the State of Arizona.

4 2. Respondent is the holder of license number 17176 for the practice of
5 allopathic medicine in the State of Arizona.

6 3. The Board initiated case number MD-07-0671A after receiving a complaint
7 from another governmental agency concerning Respondent's prescribing practices.
8 Subsequently, case number MD-08-0265A was initiated after the Board directed Staff to
9 open an investigation following Respondent's admission to taking Xanax without a
10 prescription and prescribing Xanax to a family member on two occasions.

11 4. Several patients presented to Respondent for various complaints including
12 erectile dysfunction, low energy, underactive sex drive, and anti-aging therapy.
13 Respondent evaluated the patients and prescribed various medications that included
14 human growth hormone (HGH), testosterone, Armour thyroid, Vioxx and Voltarin XR.
15 There was inadequate documentation that after the initial visit of each patient Respondent
16 performed physical examinations, other than checking vital signs and body fat percentage,
17 or ordered follow up lab studies to support the continued prescribing of the medications.
18 There also was inadequate documentation that he monitored the patients for side effects
19 from the medications. Additionally, there was no indication that Respondent directly
20 discussed his prescribing with the hematologist of patients DH who had a history of acute
21 myelogenous leukemia (AML) and JD who had a history of Non-Hodgkin's Lymphoma.

22 5. Further, patients CS's, JG's, JM's and MW's initial physical exam showed
23 that their testicles appeared slightly atrophied bilaterally. Despite this, Respondent did not
24 perform a volume measurement or document the consistency of the testicles. Patient DH
25 contacted Respondent and reported an addiction to Diazepam and Valium. Respondent

1 agreed to assist him in a weaning schedule; however, there was no documentation of this
2 agreement. On several occasions, DH contacted Respondent and requested a prescription
3 for Diazepam and Valium. Respondent authorized several prescriptions for Diazepam
4 within a thirty day period. Respondent also authorized several refills for excessive amounts
5 of Valium without the structured care of an addiction specialist. For patient MC,
6 Respondent performed a bone density test on his right hand that showed osteopenic
7 range for females rather than males. There was no documentation of this finding and
8 whether it was communicated to MC.

9 6. Patient NM contacted Respondent complaining of hand and feet numbness
10 and tingling. Respondent gave her the option of discontinuing the GH for five days or to
11 lower the dosage. Additionally, Respondent changed her estrogen and progesterone
12 protocol prescribed by her gynecologist even though she did not have any complaints
13 regarding the therapy and had good lab responses to the dosing. For patient RM,
14 Respondent noted abnormal liver functions, a left kidney cyst, and anemia. Respondent
15 referred him to an internist for a kidney ultrasound. Respondent also discontinued
16 prescribing GH, but later resumed prescribing without documenting it in RM's chart. There
17 was no documentation that Respondent communicated this with RM's internist. For patient
18 ML, who had a history of cancer and was taking Armour thyroid and aspirin, Respondent
19 prescribed Vioxx for his arthritis without counseling regarding gastrointestinal risks of
20 combining Vioxx with aspirin. Respondent also did not document a joint exam to support
21 his prescription for Vioxx. Subsequently, ML contacted Respondent complaining of
22 palpitations. Without ordering any labs to assess his thyroid, Respondent told him to
23 discontinue the Armour thyroid. Respondent also prescribed Ambien and Valtrex to ML
24 without performing a physical exam or ordering any labs. Additionally, there was no
25 documentation of a prior prescription for Valtrex. For a year, Respondent did not see ML

1 and he came in on March 4, 2005 and stated that he illegally acquired testosterone and
2 GH. Despite previous documentation that ML had abused these medications, that he had
3 acquired them illegally, and that there were no labs for over a year, Respondent resumed
4 prescribing to him. For patient JM, there was evidence that he obtained illegal steroids;
5 however, Respondent did not document this in JM's chart.

6 7. Additionally, there was inadequate documentation that Respondent followed
7 up on various abnormal findings, including CS's and RM's elevated blood pressure; JD's
8 and SG's elevated blood sugar levels; markers for potential cardiovascular disease for
9 MC; CG's and ML's elevated hematocrit levels; abnormal labs significant for leukocytosis
10 for CP; and abnormal finding of inguinal lymphadenopathy for JM .

11 8. On May 24, 2007, Respondent was ordered to undergo a drug test that was
12 positive for Alprazolam. On June 8, 2007, during an investigational interview with Staff,
13 Respondent admitted that he took a one-half tablet of Xanax without a prescription. At a
14 second investigational interview on June 20, 2007, Respondent admitted that he
15 prescribed Xanax to his brother-in-law (FS) on two occasions. Staff obtained pharmacy
16 surveys that showed on May 18, 2006, FS filled a prescription for Xanax prescribed by
17 Respondent.

18 9. The standard of care requires a physician to perform physical exams and lab
19 studies prior to continuing medications; to monitor the patients for side effects from the
20 medications; to address abnormal clinical and lab findings; to communicate any
21 prescribing with the patient's other providers; to communicate abnormal findings or a
22 changed protocol with the patient; to counsel a patient on the gastrointestinal risks of
23 combining medications; and to wean a patient's Valium under the structured care of an
24 addiction specialist when the Valium dose is greater than 20 mg per day. The standard of
25

1 care also requires a prescription from another physician for a controlled substance and to
2 not prescribe a controlled substance to an immediate family member.

3 10. Respondent deviated from the standard of care because he did not perform
4 sufficient physical exams and lab studies after the initial visits prior to continuing
5 medications; he did not consistently address abnormal clinical and lab findings; he did not
6 adequately communicate his prescribing with the patient's other providers; he did not
7 communicate the abnormal findings with MC or a change in the gynecologist's protocol
8 with NM; he did not counsel RM on the gastrointestinal risks of combining medications;
9 and he did not wean DH from Valium under the structured care of an addiction specialist.
10 Respondent also did not receive a prescription for Xanax from another physician and he
11 prescribed Xanax to an immediate family member.

12 11. There was a risk of side effects from medications not clinically indicated,
13 possible recurrence of DH's AML and possible withdrawal seizures with inappropriate
14 withdrawal from Valium. Additionally, there was potential for abuse of controlled
15 substances or overdose if FS gave misinformation and was receiving the same medication
16 from multiple providers.

17 12. A physician is required to maintain adequate legible medical records
18 containing, at a minimum, sufficient information to identify the patient, support the
19 diagnosis, justify the treatment, accurately document the results, indicate advice and
20 cautionary warnings provided to the patient and provide sufficient information for another
21 practitioner to assume continuity of the patient's care at any point in the course of
22 treatment. A.R.S. § 32-1401(2). Respondent's records were inadequate because there
23 was inadequate documentation he performed physical examinations, ordered follow up lab
24 studies, that he resumed medications, or discussed his prescribing with other current
25 providers.

1 **CONCLUSIONS OF LAW**

2 1. The Board possesses jurisdiction over the subject matter hereof and over
3 Respondent.

4 2. The conduct and circumstances described above constitute unprofessional
5 conduct pursuant to A.R.S. § 32-1401 (27)(e) ("failing or refusing to maintain adequate
6 records on a patient."); A.R.S. § 32-1401 (27)(g) ("using controlled substances except if
7 prescribed by another physician for use during a prescribed course of treatment."); A.R.S.
8 § 32-1401 (27)(h) ("prescribing or dispensing controlled substances to members of the
9 physician's immediate family.") and A.R.S. § 32-1401(27)(q) ("any conduct or practice
10 that is or might be harmful or dangerous to the health of the patient or the public.").

11 **ORDER**

12 IT IS HEREBY ORDERED THAT:

- 13 1. Respondent is issued a Decree of Censure.
14 2. This Order is the final disposition of case number MD-07-0617A and MD-08-
15 0265A.

16 DATED AND EFFECTIVE this 2ND day of APRIL, 2009.



ARIZONA MEDICAL BOARD

By


Lisa S. Wynn
Executive Director

22 ORIGINAL of the foregoing filed
this 2nd day of April, 2009 with:

23 Arizona Medical Board
24 9545 E. Doubletree Ranch Road
Scottsdale, AZ 85258

25 EXECUTED COPY of the foregoing mailed
this 2nd day of April, 2009 to:

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Debra Hill
Osborn Maledon
The Phoenix Plaza, 21st Floor
Phoenix, AZ 85012

EXECUTED COPY of the foregoing mailed
this 2nd day of April, 2009 to:

Eli J. Hammer, M.D.
Address of Record

Kenneth Corley
Investigational Review